Callio Therapeutics appoints former Sierra Oncology CSO, Chris Hassig
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Callio Therapeutics announced the appointment of Chris Hassig as Chief Scientific Officer. Hassig will lead the company's research and discovery organization, overseeing the advancement of its dual-payload antibody-drug conjugates platform. Hassig previously served as CSO of Sierra Oncology, which was acquired by GSK.
From mykxlg.com
Why it matters
The appointment brings experience in translating cutting-edge science into differentiated therapies to Callio Therapeutics. This move supports the advancement of Callio's dual-payload ADC platform in the targeted cancer therapy market.
From mykxlg.com
Who's involved
- GSKAcquired Sierra Oncology, where Chris Hassig previously served as CSO.
- Sanjay GurunathanFormer CSO of Sierra Oncology and current Chief Scientific Officer of Callio Therapeutics.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Sanjay GurunathanSpeculative
Callio Therapeutics might see changes in R&D costs or investment as it advances its ADC platform.
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- GSK and Novartis are identified as major pharmaceutical companies.